Table 2.

Clinical parameters and complement profile in patients with HELLP syndrome and severe preeclampsia

Patient	Disease Phase	Creatinine (0.3–1.3 mg/dl)	Hemoglobin (14–18 g/dl)	Platelets (130–400 109/L)	Proteinuria (mg/gr)	Blood Pressure (mm Hg)	Ankle Edema	Glutamic Oxaloacetic Transaminase (5–40 U/L)	Glutamic Pyruvic Transaminase (5–40 U/L)	Serum C3 (0.8–1.9 g/L)	Serum C4 (0.1–0.5 g/L)	Serum 50% Hemolytic Complement (28–60 U/mL)	Activated-Plasma C5b-9 Deposits (Mean±SEM)
H-1	Acute (26 wk of pregnancy)	0.6	8.3	100	452	177/111	No	73	65	1.3	0.3	43.5	8.7±1a
	Quarantine	0.6	10	125	110	120/82	No	14	26	0.9	0.3	42	3.8±0.2a
	7 mo from delivery	N.D.	N.D.	N.D.	N.D.	N.D.	No	N.D.	N.D.	1.0	0.3	32	1.2±0.1
H-2	Acute (37.5 wk of pregnancy)	2.8	11.2	63	6434	220/120	Yes	864	433	0.6	0.1	25	15.4±0.5a
	Quarantine	0.9	11.7	351	216	115/80	No	99	276	1.3	0.6	48.5	9.1±0.2a
	8 mo from delivery	N.D.	N.D.	N.D.	N.D.	N.D.	No	N.D.	N.D.	1.3	0.3	49	1.1±0.1
H-3	Acute (34 wk of pregnancy)	1.1	10.2	55	910	180/118	Yes	1628	847	1.2	0.1	14	7.8±1a
	Quarantine	0.6	11.9	382	145	116/78	No	37	71	1.8	0.4	50.5	6±1.2a
	9 mo from delivery	N.D.	N.D.	N.D.	N.D.	N.D.	No	N.D.	N.D.	1.6	0.3	50	1.2±0.2
PE-1	Acute (24.6 wk of pregnancy)	0.5	10.6	147	1059	161/84	No	44	36	13	0.3	45	2.3±0.8a
	Quarantine	0.7	13.6	211	71	133/87	No	23	18	1.4	0.5	42	0.9±0.1
	6/9 mo from delivery	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.
PE-2	Acute (26 wk of pregnancy)	0.6	12.5	222	638	170/110	No	19	30	1.3	0.1	49	2.4±0.8a
	Quarantine	0.8	12.3	306	50	118/69	No	20	40	1.6	0.4	53	0.6±0.2
	9 mo from delivery	N.D.	N.D.	N.D.	N.D.	N.A.	No	N.D.	N.D.	1.1	0.3	48	0.8±0.2
PE-3	Acute (35.2 wk of pregnancy)	1.0	11.7	135	2036	147/90	No	65	51	0.6	0.2	27	3.9±0.1a
	Quarantine	1.0	12.0	296	N.D.	109/56	No	21	28	1.5	0.4	58	1.5±0.1a
	7 mo from delivery	N.D.	N.D.	N.D.	N.D.	N.D.	No	N.D.	N.D.	1.3	0.4	59	0.6±0.1
PE-4	Acute (34.4 wk of pregnancy)	0.6	13.2	83	1102	160/110	No	25	21	1.8	0.3	63	1.5±0.14a
	Quarantine	0.6	14.0	104	222	98/55	No	25	47	1.5	0.3	39	1.0±0.1
	6 mo from delivery	N.D.	N.D.	N.D.	N.D.	N.D.	No	N.D.	N.D.	1.5	0.3	39	0.7±0.1
PE-5	Acute (34 wk of pregnancy)	1.2	12.1	201	298	174/99	Yes	160	286	1.1	0.2	52	2.6±0.12a
	Quarantine	0.6	12.2	289	55	113/58	No	20	27	1.5	0.3	57	1.5±1a
	6/9 mo from delivery	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.
PE-6	Acute (33.4 wk of pregnancy)	0.6	14.3	117	5028	139/87	No	74	110	1.1	0.2	48	1.1±0.1
	Quarantine	0.5	15.5	282	253	123/76	No	27	46	1.3	0.3	52.5	0.8±0.1
	9 mo from delivery	N.D.	N.D.	N.D.	N.D.	N.D.	No	N.D.	N.D.	1.09	0.19	38.5	1.2±0.1
PE-7	Acute (34 wk of pregnancy)	0.6	10.2	282	2024	170/100	Yes	37	19	1.6	0.4	58	2.1±0.1a
	Quarantine	0.5	11.9	371	63	106/63	No	22	15	1.5	0.3	56	N.D.
	6/9 mo from delivery	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.

Statistical analysis was performed with raw data using the t test for paired samples. H-1, patient 1 with HELLP; N.D., not done; PE-1, patient 1 with preeclampsia; N.A., not available.

^aValues statistically different than control values.